ArticleBlood2018
Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies.Molecular therapy. Oncology · 2026Review
- The MOGA multi-modal framework based on graph augmentation networks for drug response prediction.iScience · 2026Article
- Targeting SET to counteract Lyn activation demonstrates anti-cancer potential in diffuse large B-cell lymphoma.Clinical and experimental medicine · 2025Article
- Serine/threonine/tyrosine kinase 1 drives pancreatic carcinogenesis via GSK3β sequestration-mediated Wnt/β-catenin pathway hyperactivation.Signal transduction and targeted therapy · 2025Article
- USP13 mediates resistance to Ibrutinib in diffuse large B-cell lymphoma via augmenting FHL1 stabilization.American journal of cancer research · 2025Article
- Development of patient-derived lymphomoids with preserved tumor architecture for lymphoma therapy screening.Nature communications · 2024Article
- Role of Fyn in hematological malignancies.Journal of cancer research and clinical oncology · 2023Review
- Single-cell landscape of primary central nervous system diffuse large B-cell lymphoma.Cell discovery · 2023Article
- Article
- Identification of pan-kinase-family inhibitors using graph convolutional networks to reveal family-sensitive pre-moieties.BMC bioinformatics · 2022Article
- The functional roles of the circRNA/Wnt axis in cancer.Molecular cancer · 2022Review
- Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines.Journal of veterinary research · 2021Article
- Histone acetylation dynamics modulates chromatin conformation and allele-specific interactions at oncogenic loci.Nature genetics · 2021Article
- Review
- Review
- Repurposing dasatinib for diffuse large B cell lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.Journal of experimental & clinical cancer research : CR · 2019Article
- The future of kinase inhibitors for DLBCL?Blood · 2018Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
In diffuse large B-cell lymphoma (DLBCL), activation of the B-cell receptor (BCR) promotes multiple oncogenic signals, which are essential for tumor proliferation. Inhibition of the Bruton's tyrosine kinase (BTK), a BCR downstream target, is therapeutically effective only in a subgroup of patients with DLBCL. Here, we used lymphoma cells isolated from patients with DLBCL to measure the effects of targeted therapies on BCR signaling and to anticipate response. In lymphomas resistant to BTK inhibition, we show that blocking BTK activity enhanced tumor dependencies from alternative oncogenic signals downstream of the BCR, converging on MYC upregulation. To completely ablate the activity of the BCR, we genetically and pharmacologically repressed the activity of the SRC kinases LYN, FYN, and BLK, which are responsible for the propagation of the BCR signal. Inhibition of these kinases strongly reduced tumor growth in xenografts and cell lines derived from patients with DLBCL independent of their molecular subtype, advancing the possibility to be relevant therapeutic targets in broad and diverse groups of DLBCL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.